Related Experiment Video
Updated: Feb 12, 2026

DNA Vector-based RNA Interference to Study Gene Function in Cancer
Published on: June 4, 2012
Replication-incompetent gammaretroviral and lentiviral vector-based insertional mutagenesis screens identify prostate
Victor M Bii1, Casey P Collins1, Jonah D Hocum1
1College of Pharmacy, Washington State University, Spokane 99210, WA, USA.
Abstract:
Replication-incompetent gammaretroviral (γRV) and lentiviral (LV) vectors have both been used in insertional mutagenesis screens to identify cancer drivers. In this approach the vectors stably integrate in the host cell genome and induce cancers by dysregulating nearby genes. The cells that contain a retroviral vector provirus in or near a proto-oncogene or tumor suppressor are preferentially enriched in a tumor. γRV and LV vectors have different integration profiles and genotoxic potential, making them potentially complementary tools for insertional mutagenesis screens. We performed screens using both γRV and LV vectors to identify driver genes that mediate progression of androgen-independent prostate cancer (AIPC) using a xenotransplant mouse model. Vector transduced LNCaP cells were injected orthotopically into the prostate gland of immunodeficient mice. Mice that developed tumors were castrated to create an androgen-deficient environment and metastatic tumors that developed were analyzed. A high-throughput modified genomic sequencing PCR (MGS-PCR) approach identified the positions of vector integrations in these metastatic tumors. OR2A14, FER1L6, TAOK3, MAN1A2, MBNL2, SERBP1, PLEKHA2, SPTAN1, ADAMTS1, SLC30A5, ABCC1, SLC7A1 and SLC25A24 were identified as candidate prostate cancer (PC) progression genes. TAOK3 and ABCC1 expression in PC patients predicted the risk of recurrence after androgen deprivation therapy. Our data shows that γRV and LV vectors are complementary approaches to identify cancer driver genes which may be promising potential biomarkers and therapeutic targets.
Insights
This study used gammaretroviral (γRV) and lentiviral (LV) vectors to identify genes driving prostate cancer progression. Complementary vector approaches revealed new candidate genes and potential biomarkers for predicting recurrence risk in patients.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Insertional mutagenesis screens using replication-incompetent gammaretroviral (γRV) and lentiviral (LV) vectors are established methods for identifying cancer driver genes.
- These vectors integrate into the host genome, potentially dysregulating nearby genes and leading to cancer development.
- γRV and LV vectors possess distinct integration profiles and genotoxic potentials, suggesting they can serve as complementary tools for mutagenesis screens.
Purpose of the Study:
- To identify driver genes involved in the progression of androgen-independent prostate cancer (AIPC).
- To leverage the complementary strengths of both γRV and LV vectors in insertional mutagenesis screens.
- To discover potential biomarkers and therapeutic targets for prostate cancer.
Main Methods:
- Utilized a xenotransplant mouse model with orthotopically injected, vector-transduced LNCaP cells.
- Induced an androgen-deficient environment through castration to promote metastatic tumor development.
- Employed a high-throughput modified genomic sequencing PCR (MGS-PCR) to identify vector integration sites in metastatic tumors.
Main Results:
- Identified thirteen candidate prostate cancer progression genes: OR2A14, FER1L6, TAOK3, MAN1A2, MBNL2, SERBP1, PLEKHA2, SPTAN1, ADAMTS1, SLC30A5, ABCC1, SLC7A1, and SLC25A24.
- Found that the expression of TAOK3 and ABCC1 in prostate cancer patients predicted the risk of recurrence following androgen deprivation therapy.
- Demonstrated the complementary utility of γRV and LV vectors in uncovering cancer driver genes.
Conclusions:
- Gammaretroviral (γRV) and lentiviral (LV) vectors are complementary tools for identifying cancer driver genes.
- The identified candidate genes, particularly TAOK3 and ABCC1, show promise as potential biomarkers for prostate cancer recurrence.
- These findings highlight novel therapeutic targets for prostate cancer progression.
More Related Videos
Related Concept Videos
In-vitro Mutagenesis
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Chromosome Replication
Replication in Prokaryotes
DNA Replication
Replication in Prokaryotes
DNA replication...
Replication in Eukaryotes

